Tempus AI Set to Report Q2 Earnings Amid Pending Acquisition
Health-tech firm Tempus AI (TEM) is scheduled to release its second-quarter earnings report after the market closes on July 30, 2026. The company operates in a rapidly growing AI healthcare sector projected to reach $868 billion by 2030 and serves major pharmaceutical clients with its data-driven precision medicine platform. Investors are also closely watching Tempus' pending acquisition of Personalis (PSNL), valued at approximately $1.5 billion, which is expected to expand the company's capabilities in minimal residual disease monitoring for cancer patients. The deal has already faced a mixed market reaction, with shares dropping 7.74% intraday following its announcement on July 20. Despite strong revenue growth and significant data assets (over 500 petabytes), Tempus continues to face profitability concerns and stock volatility. Its forward price-to-sales ratio remains above the industry average.
Topics: AI Technology Financial Markets Healthcare